Another year , another layoff. People disappear without trace. Not J&J we knew 25 years ago. What happened to the loyalty to American workers?

Quote















anonymous said:
Reputation Reputation Reputation
Click to expand...
If they do it covertly, they can probably do rolling layoffs that are under the minimum WARN threshold. Also, “out of respect for all those impacted”, they don’t report anything internal or external. This is yet another effective “cover” without releasing details.
 




Expect sales to continue declining, at least in MedTech—it's an absolute mess. Supply Chain taking the lead on both LCM and New Product, and it's not going well for most BUs. SC and Aldo are driving the MedTech business into the ground. 25+ years with J&J and I've never seen anything this bad.
 








J&J is the BIGGEST scumbag corporation ever to exist. They call themselves the, "FAMILY COMPANY".....what a load of happy horse shit.
With their CREDO BULLSHIT & robot management VP's. THEY RUIN EVERYTHING THEY TOUCH!!! You get bought by J&J; your company is DOOMED!!!!!
 






anonymous said:
J&J is the BIGGEST scumbag corporation ever to exist. They call themselves the, "FAMILY COMPANY".....what a load of happy horse shit.
With their CREDO BULLSHIT & robot management VP's. THEY RUIN EVERYTHING THEY TOUCH!!! You get bought by J&J; your company is DOOMED!!!!!
Click to expand...
Hey stupid its SC Johnson that’s a family company not J&J.

Your really dumb, must be from the Ebony tribe.
 




anonymous said:
Expect sales to continue declining, at least in MedTech—it's an absolute mess. Supply Chain taking the lead on both LCM and New Product, and it's not going well for most BUs. SC and Aldo are driving the MedTech business into the ground. 25+ years with J&J and I've never seen anything this bad.
Click to expand...
Which business is not doing well? All businesses had strong results last year.
 


anonymous said:
Which business is not doing well? All businesses had strong results last year.
Click to expand...
? All had strong results? EPS per share fell $13.88 to $5.84 from 2023 to 2024. Additionally, growth expectations are negative for the next two quarters and more than half less that S&P 500 peers later quarters 2025. JNJ shares have significantly lagged peers over the last five years when looking at equivalent drug and medtech indexes. JNJ needs to continue to rightsize to address pension and health insurance for 130000 employees (which ironically been at that level for two years when they have “cut” 20000 to 30,000) that only escalate in cost. Also, add all the lawsuits that hangover JNJ, they need to find savings somewhere.
 



Write your reply...
Top Bottom
Back
Quote